Can a simple MRI and blood test catch pancreatic cancer earlier?

NCT ID NCT07723781

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This pilot study tests whether a structured case-finding pathway can help detect pancreatic cancer earlier in Swiss primary care. Adults aged 60 or older with warning signs like new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer are invited to undergo an MRI scan and a blood test for a biomarker called PancreaSure. The goal is to see if this approach is feasible and safe, paving the way for a larger national study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Structured case-finding pathway including MRI/MRCP and PancreaSure blood biomarker assay
What this could lead to
If successful, this approach could enable earlier detection of pancreatic cancer, potentially improving survival rates.
What could go wrong
This is a small pilot study focused on feasibility, not on proving the pathway works. The biomarker test is still exploratory, and false positives could lead to unnecessary procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY DETECTION OF CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Onkozentrum Zürich AG

    Zurich, Canton of Zurich, 8038, Switzerland

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.